HTG Molecular Diagnostics Stock Forecast, Price & News

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

Is HTG Molecular Diagnostics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HTG Molecular Diagnostics stock.
View analyst ratings for HTG Molecular Diagnostics or view top-rated stocks.

What stocks does MarketBeat like better than HTG Molecular Diagnostics?

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a drop in short interest in August. As of August 31st, there was short interest totaling 171,800 shares, a drop of 35.4% from the August 15th total of 265,800 shares. Based on an average daily trading volume, of 85,400 shares, the short-interest ratio is presently 2.0 days.
View HTG Molecular Diagnostics' Short Interest.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for HTG Molecular Diagnostics.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) posted its earnings results on Thursday, May, 13th. The medical research company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.15. The medical research company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $1.40 million. HTG Molecular Diagnostics had a negative net margin of 218.26% and a negative trailing twelve-month return on equity of 112.47%.
View HTG Molecular Diagnostics' earnings history.

What price target have analysts set for HTGM?

2 analysts have issued twelve-month price objectives for HTG Molecular Diagnostics' shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $9.50 in the next year. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for HTG Molecular Diagnostics or view top-rated stocks among Wall Street analysts.

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:

• John L. Lubniewski, President, Chief Executive Officer & Director
• Shaun D. McMeans, CFO, Secretary, Treasurer & SVP-Administration
• Byron T. Lawson, Chief Commercial Officer & Senior Vice President
• Laura L. Godlewski, Chief Accounting Officer & Vice President-Finance
• Sam M. Rua, Senior VP-Regulatory Affairs & Quality Systems

What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?

11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of HTG Molecular Diagnostics' key competitors?

Some companies that are related to HTG Molecular Diagnostics include Precipio (PRPO), Astrotech (ASTC), SeqLL (SQL), Scientific Industries (SCND), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH), Arrayit (ARYC), PositiveID (PSID), DiaSys (DYXC) and Orthometrix (OMRX).
View all of HTGM's competitors.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (8.42%), Cowen Prime Advisors LLC (7.85%), Samjo Capital LLC (7.35%), Vanguard Group Inc. (3.35%), Blue Water Life Science Advisors LLC (1.99%) and Worth Venture Partners LLC (1.97%).
View institutional ownership trends for HTG Molecular Diagnostics.

Which major investors are selling HTG Molecular Diagnostics stock?

HTGM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, and Blue Water Life Science Advisors LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or view top insider-selling stocks.

Which major investors are buying HTG Molecular Diagnostics stock?

HTGM stock was purchased by a variety of institutional investors in the last quarter, including Cowen Prime Advisors LLC, AIGH Capital Management LLC, Vanguard Group Inc., Samjo Capital LLC, Worth Venture Partners LLC, Morgan Stanley, Morgan Stanley, and PDT Partners LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or or view top insider-buying stocks.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $6.01.

How much money does HTG Molecular Diagnostics make?

HTG Molecular Diagnostics has a market capitalization of $44.53 million and generates $8.55 million in revenue each year. The medical research company earns $-20,870,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis.

How many employees does HTG Molecular Diagnostics have?

HTG Molecular Diagnostics employs 84 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

Where are HTG Molecular Diagnostics' headquarters?

HTG Molecular Diagnostics is headquartered at 3430 E. GLOBAL LOOP, TUCSON AZ, 85706.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at (520) 547-2827.